231 related articles for article (PubMed ID: 20572123)
1. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
2. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
3. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
Freidlin B; Breathnach OS; Johnson BE
Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
[TBL] [Abstract][Full Text] [Related]
4. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
5. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
6. Improving the design of phase II trials of cytostatic anticancer agents.
Stone A; Wheeler C; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
[TBL] [Abstract][Full Text] [Related]
7. Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.
Kim DW; Shyr Y; Chen H; Akerley W; Johnson DH; Choy H
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1029-36. PubMed ID: 15913910
[TBL] [Abstract][Full Text] [Related]
8. Analyzing longitudinal data with patients in different disease states during follow-up and death as final state.
le Cessie S; de Vries EG; Buijs C; Post WJ
Stat Med; 2009 Dec; 28(30):3829-43. PubMed ID: 19876950
[TBL] [Abstract][Full Text] [Related]
9. A parametric model for long-term follow-up data from phase III breast cancer clinical trials.
Jeong JH; Jung SH; Wieand S
Stat Med; 2003 Feb; 22(3):339-52. PubMed ID: 12529867
[TBL] [Abstract][Full Text] [Related]
10. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
12. Semiparametric estimation of proportional mean residual life model in presence of censoring.
Chen YQ; Jewell NP; Lei X; Cheng SC
Biometrics; 2005 Mar; 61(1):170-8. PubMed ID: 15737090
[TBL] [Abstract][Full Text] [Related]
13. Joint models for efficient estimation in proportional hazards regression models.
Slasor P; Laird N
Stat Med; 2003 Jul; 22(13):2137-48. PubMed ID: 12820279
[TBL] [Abstract][Full Text] [Related]
14. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
15. Selection designs for pilot studies based on survival.
Liu PY; Dahlberg S; Crowley J
Biometrics; 1993 Jun; 49(2):391-8. PubMed ID: 8369375
[TBL] [Abstract][Full Text] [Related]
16. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
[TBL] [Abstract][Full Text] [Related]
17. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
18. Modelling associations between time-to-event responses in pilot cancer clinical trials using a Plackett-Dale model.
Tibaldi F; Barbosa FT; Molenberghs G
Stat Med; 2004 Jul; 23(14):2173-86. PubMed ID: 15236423
[TBL] [Abstract][Full Text] [Related]
19. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
BMJ; 1995 Oct; 311(7010):899-909. PubMed ID: 7580546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]